Short answer
Axogen, Inc. (AXGN) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $76M (up 26.2% year over year) with net income of $2M.
Q3 2026 key financials · XBRL
- Revenue
- $76M
- +26.2% YoY · +8.8% QoQ
- Net income
- $2M
- +229.7% YoY · +254.0% QoQ
- Operating margin
- 1.3%
- Gross margin
- 74.8%
- EPS (diluted)
- $0.05
- +400.0% YoY · +350.0% QoQ
Source: XBRL data from the Axogen, Inc. (AXGN) Q3 2026 10-Q on SEC EDGAR. USD.
Axogen, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $75,834, up $15,752 or 26.2% YoY, driven by higher unit volume and pricing
- Gross margin 74.8% vs 76.6% YoY, pressured by higher product costs
- Q3 net income $2,334, or 3.1% margin, vs $720, or 1.2% YoY
- Cash, equivalents and investments $348,068, up from $41,528; nine-month operating cash flow $25,322 vs $(2,226)
- $225,029 offering proceeds, $200,000 allocated to BioCircuit acquisition; trade disputes and macroeconomic instability potential headwinds
Risk Factors
- Newly added merger-integration risk: BioCircuit acquisition may create costly, time-consuming integration challenges
- Operational risk: Management distraction and integration disruptions could impair existing operations
- Financial risk: Failure to realize anticipated Merger benefits could adversely affect financial condition and results of operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axogen, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.